Isolating bacteria directly from blood or positive blood culture present a unique set of problems for clinical microbiologists and researchers. We are happy that multiple recent studies using our Separation Cartridge have performed very well in both applications. This post relates to the positive blood culture application.
One ongoing study at a local hospital has observed that traditional ID results could be obtained within a day (whereas without using the cartridge results have taken 2-5 days) and that the ID results obtained using the cartridge matches that obtained by subculturing.
The shorter time-to-result using the cartridge was because it eliminated the need for subculturing decreasing the time to ID & AST by at least 24 hours. While it is generally accepted that that direct testing of positive blood culture broths is feasible, results have been variable (for instance better success with Gram-negative rods (GNR) than Gram-positive cocci (GPC)), workflow sub-optimal, or the method too expensive.
Preliminary experiences indicate that the cartridge does not have these limitations. The process takes ≤ 5 minutes, requires no new instrumentation, and uses one buffer that can be easily sourced. Results have been consistent regardless of whether it is GNR / GPC. More studies are taking place at other hospitals and microbiology labs that we will keep you updated on.
If this is an area of interest to you or your organization, please contact us (www.3idx.com). We are interested in setting up demos and additional studies to assess performance in different settings and applications. Thank you.
The Seventy-fifth World Health Assembly is being held in Geneva, Switzerland, from May 22-28, 2022. It is the first in-person Health Assembly since the start of the COVID-19 pandemic. On the occasion of the start of this assembly, many health-related organizations have released statements on healthcare priorities, inequities, and focus for the future.
Some of these observations relating to diagnostics caught our attention. We list four of them below and see them as further motivation for the work that we are doing at 3i Diagnostics.
The capacity to perform basic tests is available in just 1% of primary care clinics in low- and middle-income countries.
No diagnostic tests exist for 60% of the pathogens identified by the World Health Organization (WHO) as having the greatest outbreak potential. There are also no appropriate tests for half of the top 20 diseases responsible for the most lives lost.
Using COVID tests as an example, high-income countries use COVID tests at 10–100 times the rate of middle- and low-income countries. So, if tests are not inexpensive, testing is likely to be deficient.
Early diagnosis has been consistently linked to improved health outcomes and reduced out-of-pocket spending. However, diagnosis is the weakest link in healthcare systems globally.
One of the key learnings from COVID-19 is that investing in diagnostics will be central to rapid response to outbreaks and delivering appropriate care for infections. Deficiencies in testing affect not only people’s lives, but communities and economies, as COVID-19 clearly showed.
We have a first-hand experience, thanks to COVID, of when infections become deadly. Now imagine if treatments for diseases like salmonella, tuberculosis, malaria, and other infections are ineffective because of antimicrobial resistance (AMR). This would undo almost a century of medical progress.
AMR is when microbes adapt to the antimicrobial drugs used to treat them, rendering the drugs ineffective. Every time microbes are exposed to a drug, susceptible strains die in the presence of the antibiotic, whereas resistant strains survive and then multiply without competition from the susceptible strains. Antibiotic use is on the rise, with a 40% increase in use over 10 years (2000-2010). However, around 50% of antibiotics prescribed in the US are unnecessarily or inappropriately prescribed.
Why unnecessarily? Because it takes a long time to get test results, doctors prescribe antimicrobials while they wait. Since this is basically a trial-and-error process, they may end up trying several different antimicrobials by the time they get the diagnostic result. After they get the results, they may have to prescribe something entirely new. This process basically trains the microbes how to become resistant to antibiotics.
There are two ways to address AMR. The first is creating new antimicrobial drugs that the microbes are susceptible to. While this is an important way we can combat AMR, developing new drugs is reactive, rather than proactive. As we expose microbes to these new drugs, they will begin to develop resistance. This puts us back in the same place we started, and requires continual drug development to stay ahead. Even then, there is no guarantee that researchers will be able to develop a new drug by the time a microbe becomes resistant to the old one.
The second method of addressing AMR is developing better diagnostics. Better diagnostics will allow medical professionals to know what they’re dealing with faster, which allows them to use specific and effective treatments. Since microbes are being exposed to fewer drugs, they have less opportunities to become resistant, ultimately slowing down the spread of AMR. Doctors can continue using existing antimicrobials, and it gives researchers more time to develop new ones.
Patients with an antimicrobial resistant strain of infection can expect longer hospitalizations or stays in intensive care. They will also likely need more tests, more expensive treatments, and spend more time not working, which increases the financial impact of the infection. Additionally, major surgery and many cancer treatments will be more dangerous without effective treatments for an infection. Hospital visits will be more risky, as hospital-associated infections (HAIs) are often antimicrobial resistant.
AMR also has significant impacts at the global level. 50,000 people die every year just in Europe and the US because of AMR right now, and these impacts keep getting worse as time goes on. By 2050, some researchers estimate that AMR will cause 10 million deaths, which would be 1.8 million more deaths than cancer. Additionally, Gross Domestic Product (GDP) would be 2-3.5% lower and 100 trillion dollars would be lost.
Addressing AMR promptly and decisively is imperative to lessen these catastrophic impacts. The United States government, the World Health Organization, and other organizations have urged more careful use of antibiotics in healthcare and agriculture. They have also increased their support for the discovery and development of new antibiotics and better diagnostics. In the end, it will take the government, physicians, and all of us to effectively combat the spread of AMR. At the individual level, we need to increase awareness of AMR, and do our part to avoid pressuring physicians to prescribe antibiotics, especially when they are not needed.
There has been a notion among many in the medical community that a significant proportion of the morbidity and mortality associated with COVID-19 are due to secondary bacterial infections. This notion is, in part, attributed to studies from the 2009 H1N1 epidemic (Morris et al. ) , and early reports detailing increased presence of other respiratory pathogens in COVID-19 patients (Gerberding , Zhou et al. , Zhu et al. ). Accordingly treatment of COVID-19 patients have frequently included antibiotics.
As Andrew Jacobs reported in his New York Times article, physicians heavily prescribed antibiotics for treating these patients because of this concern. It now appears that this possibility is not as pervasive or as severe as initially thought (Rawson et al.).
While the fear of opportunistic infections have not come to pass, the overuse of antimicrobials in treating COVID-19 patients has highlighted concerns about catalyzing a slower-moving crisis namely antimicrobial resistance (AMR). Overuse of antibiotics is one of the factors that induces the development of resistance and its spread, which is precisely what we have done over these past few months.
What is interesting is that in both situations, COVID-19 and AMR, the immediate challenge has been our inability to identify those patients who need urgent medical attention. The challenges in testing subjects to determine if they are COVID-positive or not are well documented. Less well recognized is the situation in tackling AMR.
In the case of AMR, while much attention has been devoted to developing new drugs, as they should, the fact is that the fundamental problem is that we do not know which drug to administer to treat the patient efficiently and rapidly. That is, it is at heart a diagnostic problem. As the US Government Accountability Office succinctly explain in their assessment of US efforts to combat AMR “Without information to guide test usage, clinicians may not be able to select appropriate treatments for their patients.”
If you think that waiting for 48-72h to know if you were COVID-positive was unacceptable, why should it be for detecting bacterial infections, which could be just as, if not more, deadly (e.g. Sepsis)? [Today, it takes 1-5 days before the physician can learn if the patient has a bacterial infection or not] As Dr. Strich of the NIH clinical center is quoted as saying, “being prepared is more cost effective in the long run” and saves lives. “Antimicrobial resistance is a problem we cannot afford to ignore.”
And yet, there is not the same sense of urgency in developing diagnostics that can rapidly determine if a patient has a bacterial or vial infection let alone what the infection-causing pathogen is. Efforts to develop better diagnostics are not sufficiently supported by either the private or the public sectors.
We should all be asking ourselves why we are not pushing, with a greater sense of urgency, for better diagnostics that will be effective in combating AMR or the next pandemic instead of just hoping that the same approaches that have been tried for 20+ years with limited success will somehow suddenly provide the solution?
These are challenging times, and we, at 3iDx, hope that you, your loved ones, friends, and colleagues are well.
The COVID-19 pandemic has impacted the world in ways not seen in modern times. One of these is to bring back the importance of diagnostics and, importantly, the ability to perform tests in a multitude of settings.
It is abundantly clear that controlling the outbreak through social distancing severely impairs a functioning society. Any strategy to “reopen” a country is highly reliant on better testing, which is central to reducing transmission and morbidity and mortality. This not only involves being able to obtain an actionable result but also encompasses producing tests at a scale commensurate with the outbreak and addressing massive challenges in the supply chain.
While DNA-based diagnostic testing offers several reasons to include in our armament of tools. Waiting multiple hours or even days before getting a result for a COVID-19 test does not strike one as an effective strategy especially when battling reagent and buffer shortages.
While high-income countries are facing challenges in meeting the diagnostic needs of their rural and semi-urban populations, these challenges are magnified in low- and middle-income countries. These countries currently have the lowest rates of testing reported to the WHO.
It feels strange to be listing these problems and areas for improvement in yet another global crisis. We had earlier observed how our response to the antimicrobial resistance crisis is being held back because of inadequate diagnostics. The needs in both crises are eerily similar. We need rapid and inexpensive diagnostics that can be scaled easily and used outside a specialized laboratory setting. The options we currently have are not it.
The current COVID-19 crisis will draw down and we will emerge stronger. But if we are to emerge wiser from this experience, we need to invest more (resources, attention, capital) in diagnostic development.
Many recent articles have called for overhauling antibiotic pricing as one of the key ways to lure investments in antibiotic development. But, its beneficial effects, in my opinion, are exaggerated.
Alarm bells are being rung with several articles over the last few weeks in the Wall Street Journal, New York Times, and The Washington Post (to name a few) discussing how challenging the climate is for antibiotic developers. Many quoted in these articles call for an overhaul of antibiotic pricing with the central thesis being that such an overhaul will provide much needed revenue and attract investment for struggling antibiotic developers, thus recharging the efforts to combat the antimicrobial crisis. But, will it?
Past efforts to increase drug prices generated a lot of opposition and much hand wringing (see infographic). Those objections were however generally directed towards very expensive cancer drugs or overpricing of drugs. But the fundamental reasons for the opposition have not disappeared.
Certainly, antibiotic developers are struggling. They do not earn anywhere close to the revenue that a successful cancer therapeutic developer would and these struggles are well documented. But what will increasing the price/reimbursement of an antibiotic really do? The thinking goes that if antibiotic developers are successful, it will draw in more money and talent creating a virtual cycle that will be self-sustaining.
But, is it self-sustaining and will it achieve its desired goals? Everyone acknowledges that the two key reasons why antibiotic developers struggle are because (a) hospitals prescribe these new drugs sparingly to avoid building up resistance to them and (b) they try a lower cost alternative first.
When decisions on which antibiotic to use are still based entirely on clinical judgment, i.e. a good educated guess, going with the lower cost option or hoarding a “drug of last resort” is logical and natural. Why do we think that increasing reimbursement will alter this behavior. And unless we do something that changes this dynamic we are not really solving the problem. We are just creating a new special interest.
Antibiotics are the lifeblood of modern medicine. And antimicrobial resistance is a global problem. If the price of the antibiotic were raised, will other countries break patents invoking “national emergencies” much as was done to get inexpensive HIV drugs?
If the drugs are inexpensive in, say India, and are used extensively there because they work, how long do you think it will be before resistance develops for these drugs?
If you went to a physician and after a visual examination, the physician recommends that you undergo cancer treatment because he/she suspects you have cancer, would you do it or would you change physicians? But, this is what we do every single day with infections and antibiotics. And if someone comes along saying the solution is to have pricier drugs, well…
Look, I get the point about reviewing pricing of antibiotics to aid discovery and development of new drugs. They need help. But, these can be one-time efforts. But, overhauling reimbursements of drugs (which sets up a long-term impact) is not the answer to combating antimicrobial resistance. It is not sustainable and will do nothing to change prescribing behaviors. When we can assure appropriate usage of antibiotics, we can influence prescription behavior and then revenues will take care of themselves.
Aha! So how do we assure appropriate usage of antibiotics? The only way I am aware of is by having a diagnostic that can truly guide treatment decisions along with improved awareness and preventive measures that hospitals are already beginning to take. If such a test were available, then physicians would not hoard. They would not try the lower cost option just because it is there. But they will pick the drug because it will provide maximum benefit to the patient. And because we will not be overusing or misusing the antibiotic, resistance spread will be slower. Note that all of these benefits can be achieved without raising drug pricing. So I would say that we should be redoubling efforts to ensure appropriate usage of antibiotics (especially new antibiotics) that meet the needs of hospitals, physicians, and patients and not fiddling with drug pricing.
You might say my position is biased because of my affiliation. It is not. But, the best way to counter my argument would be to provide a better self-sustaining model – one that helps developers, patients, and the healthcare system. Overhauling pricing helps the developers directly and very tenuously, the patients, healthcare system, or society. And as much as I relate with drug developers (having been one), such a strategy (increasing pricing/reimbursements) does not make for good policy.
New Year’s greetings and best wishes for 2020 to all!
We had ended last year, coincidentally, pondering why wide spread application of PCR-based tests in bacterial diagnostics has been elusive and identified a couple of key features that limit their use. It seems appropriate to start the new year with a discussion on one technology that can address those limitations – Infrared-based identification (IR).
What, you might be wondering, – that dilapidated instrument I vaguely recall using in undergraduate chemistry lab? Well, not quite that instrument but yes, one that utilizes the same fundamental principles.
The concept of using IR for identifying bacteria is not new. The earliest reference that we have been able to find dates back to 1950s! But, instrumental and computational limitations held back the potential for using this technology for identifying bacteria until the early 1980s. Naumann and colleagues took advantage of computational advances to demonstrate the ability of this technology to identify bacteria rapidly. Since then the use of IR for rapid and reliable identification of microbes to the strain level have been well documented. Reference databases to facilitate rapid identification of microorganisms are already available with some containing as many as 7000 strains.
How does the technology work? IR, as you may recall, is a widely used vibrational spectroscopy technique that is used to identify compounds, even those present in mixtures. It is routinely used in raw material testing in the pharmaceutical and other industries as well as in testing of milk and milk products. All of the components that make up a bacterium (proteins, lipids, sugars, etc.) contribute to an IR “fingerprint” (see figure below). The nature and concentration of these components differ from one strain to another resulting in unique IR-fingerprints. This bacterial fingerprint has been used to differentiate between multiple bacterial species and strains including differentiating between antibiotic-resistant and -susceptible strains.
Bacterial fingerprint obtained by Infrared spectroscopy. Each species and strain has a different composition and hence a unique fingerprint.
How does it compare to PCR-based identification? Two key limitations of PCR-based tests that we had discussed previously were clinical sensitivity of the test and cost per test. If a PCR-test yielded a negative result, the clinician would not have any actionable information. On the other hand, with IR-based identification, the profile of a bacteria is very distinctive and its absence clearly indicates the absence of bacteria in the sample. In such a case, the clinician can actively consider whether administering antibiotics will be of any benefit to the patient. In the case of a positive result, the actions are similar to that with a PCR-based test with several important benefits. These are:
the result is available in ≤ 10 minutes
No custom labels or reagents are needed lowering the cost per test
It does not require specialized laboratory for operation
The bacteria is intact and viable after the analysis
Antibiotic resistance can be determined
The number of species and strains that are identified can be easily expanded without requiring new primers or antibiodies. This is done as a software update that consists of the fingerprint of the new bacteria and adjustments to the recognition algorithm, if needed.
You might be wondering at this stage why, if IR has all these benefits, there has not been any IR-based commercial instrument for use in bacterial ID? There are commercial instruments from Bruker, Thermo, and others that are used for bacterial ID in food safety testing. However the methodology used today requires bacteria to be cultured prior to identification (i.e. the same as most PCR-based tests). In addition, the bacteria has to be separated from the matrix components in order to make an accurate ID. Owing to these reasons, the technology has not yet seen widespread adoption for clinical use.
It is this aspect that we have impacted with the development of our separation cartridge. As mentioned previously, our separation cartridge can isolate and concentrate intact bacteria directly from blood with minimal manual intervention. The isolated bacteria can be identified using any technique. Using it upstream of IR however, permits rapid and sensitive identification of bacteria directly from patient sample without using any bacteria-specific labels or reagents. This combination of our separation cartridge and IR-based identification will, we believe, permit rapid, inexpensive, and hypothesis-free detection and identification. We aim to demonstrate this in 2020.
As we have said before, it’s not that IR (or any other ID technique) has to wholly replace PCR-based tests. The problem is large enough that multiple solutions will be needed. But, given the history of limited gains in developing effective PCR-based bacterial ID tests, the more diagnostic options we have, the better we can aid physicians in making the best decisions for treatment while slowing the spread of antimicrobial resistant bacteria. IR-based identification presents a compelling case to be a key diagnostic option.
A common refrain in this post-antibiotic era is that we need new antibiotics and new diagnostics . While the challenges of developing a new antibiotic are better acknowledged and understood, many are very surprised that we still use fundamentally the same procedure as used pre-WWII.
So, how is it that we are, at the start of 2020 and ~30 years since the dawn of the PCR-era, still talking about the need for better bacterial diagnostics? There are multiple technical and real-world challenges that continue to stymie the development of PCR-based tests such as speed, volume that can be processed, number of bacteria identified, and so on. Sensitivity and Specificity of a PCR-based test (or rather the lack of sufficient Sensitivity and Specificity) are two key performance attributes that have held back widespread clinical use of PCR-based tests. For this discussion, we focus on identifying bacteria directly from blood for guiding treatment of bloodstream infections, especially those that might lead to severe sepsis or septic shock.
Multiple PCR-based approaches are being developed to rapidly identify bacteria from blood. To a neutral observer it would appear that the reason we do not have a suitable bacteria test is because we have not developed a good enough PCR-based test. And that suitably optimizing such a test would solve the problem. Is this correct? Or are there some fundamental limitations that have held back clinical application?
In our opinion, the fundamental technical limitation is centered around the sensitivity of PCR-based tests and a fundamental practical limitation is centered around the ability to lower costs to a level that the healthcare system can support.
There are numerous text books and reviews providing a basis for determining the sensitivity and specificity of a test. Here is one. Briefly, Sensitivity refers to how good a test is at correctly identifying people who have the disease. While Specificity is concerned with how good the test is at correctly identifying people who do not have the disease.
What can we learn from these numbers for a bacterial diagnostic based on PCR? Let’s take the case of a hospital that analyzes 100,000 bacterial ID tests a year.
The percentage of samples that turn positive upon blood culturing ranges from 5 to 10%. Using the upper end of this range it means that out of the 100,000 samples submitted for bacterial ID tests, ~10,000 turn positive. [Note: This is frequently viewed as the number of samples that actually contain bacteria though there is widespread acknowledgment that culturing underestimates the number. More on this later. But, for the moment, since culturing is the gold standard (albeit an imperfect one) let’s go with 10,000 samples out of the 100,000 samples contain bacteria and therefore represent an infection.]
Data from two commercially available PCR based tests exhibit sensitivity and specificity are shown in the table below.
Sensitivity
Specificity
Septifast ®
42.9%
88.2%
SepsiTest ®
28.6%
85.3%
The sensitivity of these two tests range from 28.6% to 42.9%. In other words, if the PCR result came back negative (suggesting there is no bacteria), you could only be ~43% sure that there really was no infection! Think about that for a moment. If you were a physician making this decision, would you decide not to administer antibiotics based on this result? You’re most likely going to administer the antibiotics as you’re not that confident that you can rely on the negative result. Similarly, the specificity of these two tests range from 85.3% to 88.2%. In this case, you can be 88% sure that if you got a positive result, the patient has an infection though there’s a 12% chance that the result may not be accurate.
Let’s apply the above numbers to our hospital that processes 100,000 blood culture samples. Suppose that these samples are tested by a PCR-based test instead of being submitted for blood culture testing. Using the Sensitivity and Specificity numbers from above, this means that, of the 100,000 samples, 15,400 will yield a positive result. But, only 4,600 of these are truly positive. So, you will end up administering antibiotics unnecessarily for a large number of patients based on the 10,800 positive results. Similarly, you would have had 84,600 negative results of which 5,400 are false negatives. This means that you would have chosen not to administer antibiotics despite patients needing it.
“True” Result
Positive
Negative
PCR test positive
4,600
10,800
PCR test negative
5,400
79,200
As a physician or a hospital, the number of incorrect decisions resulting by relying on such a test is too high – jeopardizing patient safety. Does it really provide a significant benefit over the current practice where antibiotics are administered based largely on clinical judgment? At the present moment at least, the general opinion is no. Since it does not offer significantly helpful guidance relative to current practice it does nothing to correct overuse or misuse of antibiotics.
Most of the time when we consider how to use the result from a diagnostic test, we ask ourselves, if it yields a positive result would I know what to do next? That is an important question. But, in this application, it is equally (if not more) important to ask if the test yields a negative result, would I know what to do next? There is not sufficient data (and may never be) to guide treatment decisions when a PCR-based test is negative. This is the fundamental technical limitation.
Besides their performance, PCR-based tests also create problems due to their cost and operation. A single test costs $70 – $200 based on the number of bacteria identified. Using our example, if such a test were used for each sample currently submitted for blood culture, it would cost each hospital $7-$20 million (just in consumables). Which consumes a significant portion of a microbiology lab budget leaving little to no money for other tests. And still leaves a large number of bacteria unidentified!
In theory one can design a PCR test that is multiplexed to cover a large number of bacteria. But, this will increase the cost per test. Splitting the number of bacteria identified across multiple test panels is one way of covering a broader range. But, this takes away the advantages of cost reduction due to large volumes. How does one respond to new strains or species that are of urgent concern that was not anticipated? In different regions of the world? The modifications to the manufacturing process to address these different demands make it very challenging for the manufacturer to keep costs low.
So, at a fundamental level, PCR-based tests for identifying bacteria directly from blood face limitations due to poor performance, high costs, and appear to not aid decision-making or operational efficiency.
Significantly improving sensitivity and controlling costs are therefore necessary, but not sufficient, conditions for enabling widespread use of PCR as a bacterial ID test direct from patient sample. And until they are satisfactorily resolved, there will continue to be a reluctance in using such tests to guide antibiotic treatment.
Which means that we owe it to ourselves and all patients to consider and develop alternative ID techniques. It’s not that one technique is a winner and the other the loser in such an effort. The problem is large enough that multiple solutions will be needed. The more diagnostic options we have, the better we can aid physicians in making the best decisions for treatment while slowing the spread of antimicrobial resistant bacteria.
Antibiotics and focusing on infectious diseases is not the area where brainpower and money are focused on presently. It’s not as if people have suddenly stopped getting infections or that we don’t incur huge medical care costs because of them. Three infectious diseases were ranked in the top ten causes of death worldwide in 2016 by the World Health Organization. In the US, Among major disease categories, the cost per case grew fastest for infectious diseases.
Meanwhile the cost of treating patients who develop sepsis in the hospital rose by 20% in just three years, with hospitals spending $1.5 billion more last year than in 2015. In the US, the average cost per case for hospital-associated sepsis was slightly over $70,000 in 2018 with an annual increase in incidence of nearly 13%. Each year at least 1.7 million adults develop Sepsis and one in three patients who die in a hospital have Sepsis.
So, why the apparent lack of interest in tackling the problem? The challenges with new antibiotics development have been eloquently summarized by Isaac Stoner that I would highly recommend reading regardless of whether you are interested in this space or not. This captures the challenges faced by an antibiotic developer in achieving commercial success even if they have achieved technical success (i.e. a new antibiotic that works). Largely because of these struggles, many have concluded that antibiotics development carries too high a risk with very little return presently; one just has to wait until someone finds a way to make antibiotics profitable again.
Paradoxically, the situation, impact, and incentives work the other way for diagnostics. But this does not appear to have been fully appreciated by the broader audience yet. And recent “successes” have not delivered on expectations. But the case to persist is strong.
New antibiotics struggle to achieve commercial success because they are reserved for use as a last resort. This antibiotic stewardship, which is needed, limits the number of prescriptions for the new antibiotic making it difficult to achieve profitability. Having a diagnostic determine which antibiotic to administer (new or existing) promotes stewardship and reduces both overuse and misuse of antibiotics. If done right, the volumes of these tests would be sufficiently large (100 million tests in US alone each year) to assure profitability.
Diagnosis-related Group coding (DRG; where insurers pay a lump sum to hospitals for treatment) incentivizes hospitals to use inexpensive antibiotics, which places significant pricing pressure on new expensive antibiotics. But, it also incentivizes hospitals to get the initial antibiotic right since use of appropriate antibiotics early improves patient outcomes and reduces length of stay. i.e. hospitals get to keep more of the lump sum payment increasing their profit margins. In cases like Sepsis (which is one of the most expensive conditions to treat in hospitals), this makes a huge impact. It may even be the difference between whether the hospital is able to break even or not.
So, a well-designed diagnostic approach will garner strong stakeholder (patients, payers, society) support and command large volumes needed to be successful. It is difficult for antibiotics, with the healthcare and reimbursement models in effect today, to have such support or volumes.
Challenges
The one area where antibiotic development and diagnostics development share common ground is in investment attention – both struggle for it. Even well-intentioned programs like CARB-X and NIH grants do not devote sufficient funds for diagnostics development (see chart). While several governments, notably the UK, and the WHO have been campaigning for greater investment action, there are no moonshot initiatives to combat antimicrobial resistance. All this despite evidence that an appropriate diagnostic would allow us to dramatically improve the efficiency of existing drugs and buy us time to develop other long-term strategies.
Even though the market is huge, the impact is huge, and there is a real problem in need of a solution, limited resources (human and financial) have been devoted to this area and problem. So, we find ourselves in the situation today where there is no diagnostic that can help physicians determine if an antibiotic is necessary and which one to use. The core technology we use is effectively the same since the early 20th century!
This is partly because the approaches being attempted use the same basic strategy as those that have been tried before (that did not yield desired outcomes) with advances in technology incorporated. so, it is not too surprising that they have not yielded the desired results. The willingness to adopt a high-risk high reward strategy by investors as done in areas such as oncology therapeutics has been conspicuously absent. It’s not that investors are not aware of the challenges posed by AMR and Sepsis or the need for a solution. But, there needs to beat least one good commercial success story to renew the interest in this space. The high rewards are not readily apparent to investors burned by previous approaches. New, improved technical solutions and business models have not matured/been developed either. And this paucity of solutions is only made more difficult as talent seeks the security of better-funded areas.
They have been proposals to increase the economic incentives for developing much needed antibiotics. So far these well intentioned efforts have not resulted in some technical success but not the growth of self-sustaining companies. Pragmatically the success story is more likely to come via diagnostics (for the reasons outlined above) than in therapeutics. Or through a combination of diagnostic and therapeutic approaches enabling precision medicine for infectious diseases.
Progress
Despite these challenges, we are optimistic about the prospect of new innovative solutions and our platform, Biospectrix™. The ideal diagnostic should be able to detect the presence/absence of bacteria, determine its identity, and if it is antibiotic resistant – all in 15-60 minutes. Early results in our lab indicate that we can meet all of the above requirements.
With our approach, we aim to isolate, detect, and identify bacteria in < 1 hour without destroying the bacteria. The information from the analysis is utilized by the physician to administer the appropriate antibiotic. Through this process, patient outcomes will improve, length of stay in hospitals will decrease, hospital profit margins will improve, and, crucially, we can slow down the spread of antimicrobial resistance by cutting down on inappropriate antibiotic use. This is an outcome worth persevering for.
And, by the way, once we are done with our analysis, the bacteria can be cultured (from the sample we analyzed) and subjected to further analysis, if needed, but without the time pressure.
Enabling targeted therapy will permit new antibiotics being used judiciously as opposed to simply being saved as a method of last resort when it might be too late. Judicious use would provide the volumes needed for antibiotic developers to be profitable. It would also prolong the life of existing drugs. The possibilities for individual and societal good and commercial success are tantalizing. And that is why we believe that diagnostics are the place to start to combat AMR and Sepsis.
There is still some ways to go and many challenges to overcome before this vision becomes reality. But, we do so knowing that technical and commercial success with a positive impact on patients and healthcare, as we know it, is near. Jim O’Neil stated in his assessment on antimicrobial resistance, “One of the greatest worries about AMR is that modern health systems and treatments that rely heavily on antibiotics could be severely undermined.” We intend to do our part in preventing this bleak scenario from becoming reality.
